Donanemab (brand name Kisunla; development code LY3002813) is a humanized IgG1 monoclonal antibody developed by Eli Lilly and Company for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in July 2024, donanemab became the second anti-amyloid antibody to receive traditional FDA approval, following lecanemab, representing a significant expansion in disease-modifying treatment options for Alzheimer's disease[1].
This entity profile provides a comprehensive overview of donanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: Donanemab (Kisunla) — Therapeutics.
Donanemab is a humanized IgG1 monoclonal antibody engineered for specific targeting of pyroglutamate-modified amyloid-beta (N3pG-Aβ). This specific targeting distinguishes it from other anti-amyloid antibodies and contributes to its unique efficacy and safety profile[2].
Key molecular properties:
| Property | Value |
|---|---|
| Antibody type | Humanized IgG1 |
| Molecular weight | ~150 kDa |
| Target | N3pG-Aβ (pyroglutamate-modified Aβ) |
| Target form | Deposited amyloid plaques |
| Affinity for N3pG-Aβ | High (sub-nanomolar) |
| Affinity for monomeric Aβ | Low |
| Fc region | Native (not engineered) |
Donanemab's defining feature is its specific binding to N3pG-Aβ (also written as N3pE-Aβ), a truncated and post-translationally modified form of amyloid-beta:
This specificity for plaque-enriched N3pG-Aβ differentiates donanemab from other anti-amyloid antibodies:
Donanemab exerts its therapeutic effects through several interconnected mechanisms[3]:
1. Plaque-Directed Binding
Donanemab selectively binds to N3pG-Aβ within deposited amyloid plaques, marking them for immune-mediated clearance. This binding is highly specific for the plaque environment rather than soluble Aβ species.
2. Fcγ Receptor-Mediated Phagocytosis
The antibody-opsonized plaque complexes engage Fcγ receptors on microglia, triggering phagocytosis and lysosomal degradation. This represents the primary clearance mechanism for donanemab-bound amyloid.
3. Antibody-Dependent Cellular Cytotoxicity (ADCC)
The Fc region of donanemab can engage natural killer (NK) cells and other immune effector cells, potentially contributing to plaque clearance through ADCC mechanisms.
4. Plaque Destabilization
Evidence suggests donanemab may destabilize existing amyloid plaques, facilitating their conversion to soluble aggregates that can be cleared through the mechanisms described above.
Like lecanemab, donanemab's efficacy is intimately connected to microglial biology. The antibody's plaque clearance depends on functional microglial phagocytosis, involving:
This relationship explains why genetic variants affecting microglial function may influence individual patient responses to donanemab therapy.
One of donanemab's most innovative features is its limited-duration treatment approach:
This approach offers several potential advantages:
Phase I clinical trials established:
The Phase II TRAILBLAZER-ALZ trial enrolled 272 patients with early AD[4]:
The pivotal Phase III TRAILBLAZER-ALZ 2 trial enrolled 1,736 patients with early AD[1:1]:
Following FDA approval, development continues with:
| Region | Status | Date |
|---|---|---|
| United States | FDA approved | July 2024 |
| Japan | Approved | October 2024 |
| United Kingdom | Under review | - |
| European Union | Under review | - |
| Canada | Under review | - |
Donanemab is indicated for the treatment of early Alzheimer's disease, specifically:
Patients must have confirmed amyloid pathology via PET scan or CSF biomarkers before initiating treatment.
In TRAILBLAZER-ALZ 2[1:2]:
| Endpoint | Donanemab | Placebo | Treatment Effect |
|---|---|---|---|
| CDR-SB change (18 mo) | 2.97 | 4.04 | -1.07 (35.6% slowing) |
| Amyloid reduction | 86→17 Centiloid | Minimal | 80.2% reduction |
| CSF p-tau181 | -17.3% | +3.4% | Significant reduction |
Donanemab's efficacy varies by baseline tau burden[4:1]:
| Tau Level | CDR-SB Benefit | Clinical Meaning |
|---|---|---|
| Low/Medium | Greater benefit (35.6% slowing) | Earlier intervention more effective |
| High | Moderate benefit | Advanced disease less responsive |
This stratification approach allows for personalized treatment decisions based on disease stage.
| ARIA Type | Donanemab | Placebo |
|---|---|---|
| ARIA-E (edema) | ~24% | ~2% |
| ARIA-H (hemorrhage) | ~7% | ~2% |
| Risk Factor | Impact |
|---|---|
| APOE ε4 homozygosity | Highest ARIA risk |
| APOE ε4 heterozygosity | Moderate ARIA risk |
| Prior cerebral microhemorrhages | Increased risk |
| Feature | Donanemab | Lecanemab | Aducanumab |
|---|---|---|---|
| Target | N3pG-Aβ plaques | Protofibrils | Mixed forms |
| Treatment approach | Limited duration | Continuous | Continuous |
| Dosing | 350 mg monthly | 10 mg/kg biweekly | 10 mg/kg monthly |
| Amyloid reduction | ~80% | ~81% | ~60% |
| CDR-SB benefit | 0.70-1.07 | 0.45 | 0.39 |
| ARIA-E rate | ~24% | ~13% | ~35% |
Donanemab occupies a unique position in the AD therapeutic landscape:
Choice between donanemab and lecanemab depends on:
Optimal candidates for donanemab therapy meet the following criteria:
Patients receiving donanemab require regular monitoring:
| Trial | Phase | Population | Status | Key Results |
|---|---|---|---|---|
| TRAILBLAZER-ALZ | II | Early AD (n=272) | Complete | iADRS improvement |
| TRAILBLAZER-ALZ 2 | III | Early AD (n=1,736) | Complete | Primary endpoint met |
| TRAILBLAZER-ALZ 3 | III | Preclinical AD | Recruiting | Prevention trial |
| TRAILBLAZER-ALZ 4 | III | Early AD | Recruiting | Imaging outcomes |
Despite donanemab's approval, several important questions remain:
Active research areas include:
Donanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎ ↩︎ ↩︎
Amyloid assembly and the N-terminally truncated species of amyloid-beta. Nature Neuroscience. 2017. ↩︎
Clinical pharmacokinetics of donanemab. Clinical Pharmacokinetics. 2023. ↩︎
Donanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2021. ↩︎ ↩︎
Amyloid-related imaging abnormalities in donanemab-treated patients. Neurology. 2024. ↩︎